Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Ping Wang, Tianjin Medical University, China

*CORRESPONDENCE Lincan Duan, ⊠ duanmumuhuosan@163.com

[†]These authors have contributed equally to this work

RECEIVED 27 February 2024 ACCEPTED 22 March 2024 PUBLISHED 05 April 2024

CITATION

Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X and Duan L (2024), Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/IncRNA-SNHG1/miRNA-140-3p/ UBE2C axis. *Front. Cell Dev. Biol.* 12:1392532. doi: 10.3389/fcell.2024.1392532

COPYRIGHT

© 2024 Jiang, Yuan, Tang, Wang, Liu, Zou and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms

Corrigendum: Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/ IncRNA-SNHG1/miRNA-140-3p/ UBE2C axis

Xiulin Jiang^{1†}, Yixiao Yuan^{2†}, Lin Tang², Juan Wang², Qianqian Liu², Xiaolan Zou² and Lincan Duan^{2*}

¹Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, China, ²Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China

KEYWORDS

epigenetics, SNHG1, miRNA-140-3p, UBE2C, pan-cancer, prognosis, immunotherapy, drug sensitivity

A Corrigendum on

Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/ UBE2C axis

by Jiang X, Yuan Y, Tang L, Wang J, Liu Q, Zou X and Duan L (2021). Front. Cell Dev. Biol. 9:765772. doi: 10.3389/fcell.2021.765772

In the published article, there was an error in Figure 9E as published. Due to negligence and lack of careful inspection, and this part of the sequence is very similar. Therefore, some base mapping errors occurred, the inaccurate WT sequence for SNHG1 is: UCUUUAUCUUGAGCUGUGGUA (In Figure 9E). The corrected WT sequence for SNHG1 is: AUUUUUCUACUGCUCGUGGUA. The Figure 9E caption was correct. The corrected Figure 9E appear below.

In the published article, there was an error in the **Materials and methods**, Quantitative Real-Time PCR section: primer sequences: SNHG1-F: AGCATCCACGAGCAAGAGAC, SNHG1-R: GATGCTACTAGTGTGGCGGGG.

A correction has been made to primer sequences: SNHG1-F: GCATCTCATAATCTA TCCTGG, SNHG1- R:CCTAGTTTTCCTCAAACTCCT. This sentence previously stated:

"SNHG1-F: AGCATCCACGAGCAAGAGAC, SNHG1-R: GATGCTACTAGTGTG GCGGG"

The corrected sentence appears below:

"SNHG1-QPCR-F-GCATCTCATAATCTATCCTGG, SNHG1-QPCR-R-CCTAGTT TTCCTCAAACTCCT"

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 9

Analysis of upstream IncRNA of miRNA-140-3p in pan-cancer. (A) The correlation between the SNHG1 and miRNA-140-3p in LUAD analysis by Starbase. (B) The subcellular localization of SNHG1 examined by IncLocator. (C) The coding potential of SNHG1 analysis by coding the potential calculator. (D) The expression of SNHG1 in NSCLC cell lines examined by qRT-PCR assay. (E) The target sites between miRNA-140-3p and SNHG1 was predicted by Starbase. (F,G) Relative luciferase activities of wild-type (WT) and mutated (MUT) SNHG1 reporter plasmid in A549 and H1975 cells co-transfected with miR-140-3p mimics examined by luciferase reporter assay. (H,I) The expression of UBE2C after depletion of SNHG1 in NSCLC cell lines examined by qRT-PCR assay. (J) The correlation between miRNA-140-3p and UBE2C, SNHG1 in NSCLC examined by Starbase. *p < 0.05, **p < 0.01, ***p < 0.001.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.